Education
About Us
Working with TipRanks
Follow Us
BeiGene (ONC)
NASDAQ:ONC
ONC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$141.31 - $287.88
Previous CloseN/A
VolumeN/A
Average Volume (3M)359.18K
Market Cap
$34.12B
Enterprise Value$291.90B
Total Cash (Recent Filing)$2.52B
Total Debt (Recent Filing)$996.83M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Aug 22, 2025EPS Estimate
0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding109,600,150
10 Day Avg. Volume358,691
30 Day Avg. Volume359,176
Financial Highlights & Ratios
PEG Ratio-5.38
Price to Book (P/B)67.27
Price to Sales (P/S)0.00
P/FCF Ratio-150.01
Enterprise Value/Market Cap8.55
Enterprise Value/Revenue20.27
Enterprise Value/Gross Profit82.42
Enterprise Value/Ebitda-143.50
Forecast
1Y Price Target
$333.78Price Target Upside23.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
BeiGene News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe first-ever quarterly GAAP profitability marks a significant milestone for BeiGene, driven by strong top-line growth and enhanced operating leverage.
Research And DevelopmentBeiGene is preparing to initiate Ph3 trials of BGB-43395 in HR+/HER2- breast cancer, showcasing a significant R&D milestone.
Sales PerformanceZanubrutinib achieved a leading position in the BTK inhibitor market within China, capturing a significant market share.
Bears Say
CompetitionThere are some concerns for future competition to Tevimbra in China from Akeso/Summit's ivonescimab, which is unlikely to have NRDL coverage until at least FY27.
Ownership Overview
Currently, No data available
---
ONC FAQ
What was BeiGene’s price range in the past 12 months?
BeiGene lowest stock price was $141.31 and its highest was $287.88 in the past 12 months.
What is BeiGene’s market cap?
BeiGene’s market cap is $34.12B.
When is BeiGene’s upcoming earnings report date?
BeiGene’s upcoming earnings report date is Aug 22, 2025 which is in 67 days.
How were BeiGene’s earnings last quarter?
BeiGene released its earnings results on May 07, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.531 by $0.531.
Is BeiGene overvalued?
According to Wall Street analysts BeiGene’s price is currently Undervalued.
Does BeiGene pay dividends?
BeiGene does not currently pay dividends.
What is BeiGene’s EPS estimate?
BeiGene’s EPS estimate is 0.24.
How many shares outstanding does BeiGene have?
BeiGene has 109,600,150 shares outstanding.
What happened to BeiGene’s price movement after its last earnings report?
BeiGene reported an EPS of $0 in its last earnings report, beating expectations of -$0.531. Following the earnings report the stock price went down -3.93%.
Which hedge fund is a major shareholder of BeiGene?
Currently, no hedge funds are holding shares in ONC
BeiGene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$333.78 (23.79% Upside)
$333.78 (23.79% Upside)
Blogger Sentiment
Bullish
ONC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 529.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.05%
12-Months-Change
Fundamentals
Return on Equity
-11.44%
Trailing 12-Months
Asset Growth
3.07%
Trailing 12-Months
Company Description
BeiGene
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
ONC Company Deck
ONC Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial and operational performance with significant revenue growth, market leadership, and pipeline advancements. Despite challenges in fixed-duration treatments and navigating a complex global environment, the company's strategic initiatives and investments are positioning it well for future growth.Read More>ONC Stock 12 Month Forecast
Average Price Target
$333.78
▲(23.79%Upside)